<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Musculoskelet Disord</journal-id><journal-title>BMC Musculoskeletal Disorders</journal-title><issn pub-type="epub">1471-2474</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17156423</article-id><article-id pub-id-type="pmc">1712338</article-id><article-id pub-id-type="publisher-id">1471-2474-7-98</article-id><article-id pub-id-type="doi">10.1186/1471-2474-7-98</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Serum levels of Cartilage Oligomeric Matrix Protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Andersson</surname><given-names>Maria LE</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>maria.andersson@spenshult.se</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Thorstensson</surname><given-names>Carina A</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>carina.thorstensson@spenshult.se</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Roos</surname><given-names>Ewa M</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>ewa.roos@med.lu.se</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Petersson</surname><given-names>Ingemar F</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>ingemar.petersson@spenshult.se</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Heinegård</surname><given-names>Dick</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>dick.heinegard@medkem.lu.se</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Saxne</surname><given-names>Tore</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I4">4</xref><email>tore.saxne@med.lu.se</email></contrib></contrib-group><aff id="I1"><label>1</label>Spenshult Hospital for Rheumatic Diseases, Halmstad, Sweden</aff><aff id="I2"><label>2</label>Department of Rheumatology, Clinical Sciences Lund, Lund University, Lund, Sweden</aff><aff id="I3"><label>3</label>Department of Orthopaedics, Clinical Sciences Lund, Lund University, Lund, Sweden</aff><aff id="I4"><label>4</label>Department of Experimental Medical Science, Section for Cell and Matrix Biology, Lund University, Sweden</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>7</day><month>12</month><year>2006</year></pub-date><volume>7</volume><fpage>98</fpage><lpage>98</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2474/7/98"></ext-link><history><date date-type="received"><day>29</day><month>8</month><year>2006</year></date><date date-type="accepted"><day>7</day><month>12</month><year>2006</year></date></history><permissions><copyright-statement>Copyright © 2006 Andersson et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Andersson et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="4059" xml_f="4069" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="4080" xml_f="4320" txt_i="22" txt_f="262">COMP (Cartilage oligomeric matrix protein) is a matrix protein, which is currently studied as a potential serum marker for cartilage processes in osteoarthritis (OA). The influence of physical exercise on serum COMP is not fully elucidated.</offsets></p><p><offsets xml_i="4327" xml_f="4535" txt_i="263" txt_f="471">The objective of the present study was to monitor serum levels of COMP during a randomised controlled trial of physical exercise vs. standardised rest in individuals with symptomatic and radiographic knee OA.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="4576" xml_f="4583" txt_i="473" txt_f="480">Methods</offsets></title><p><offsets xml_i="4594" xml_f="5261" txt_i="481" txt_f="1148">Blood samples were collected from 58 individuals at predefined time points before and after exercise or rest, one training group and one control group. The physical exercise consisted of a one-hour supervised session twice a week and daily home exercises. In a second supplementary study 7 individuals were subjected to the same exercise program and sampling of blood was performed at fixed intervals before, immediately after, 30 and 60 minutes after the exercise session and then with 60 minutes interval for another five hours after exercise to monitor the short-term changes of serum COMP. COMP was quantified with a sandwich-ELISA (AnaMar Medical, Lund, Sweden).</offsets></p></sec><sec><title><offsets xml_i="5283" xml_f="5290" txt_i="1150" txt_f="1157">Results</offsets></title><p><offsets xml_i="5301" xml_f="5823" txt_i="1158" txt_f="1677">Before exercise or rest no significant differences in COMP levels were seen between the groups. After 60 minutes exercise serum COMP levels increased (p &lt; 0.001). After 60 minutes of rest the serum levels decreased (p = 0.003). Median serum COMP values in samples obtained prior to exercise or rest at baseline and after 24 weeks did not change between start and end of the study. In the second study serum COMP was increased immediately after exercise (p = 0.018) and had decreased to baseline levels after 30 minutes.</offsets></p></sec><sec><title><offsets xml_i="5845" xml_f="5855" txt_i="1679" txt_f="1689">Conclusion</offsets></title><p><offsets xml_i="5866" xml_f="6354" txt_i="1690" txt_f="2178">Serum COMP levels increased during exercise in individuals with knee OA, whereas levels decreased during rest. The increased serum COMP levels were normalized 30 minutes after exercise session, therefore we suggest that samples of blood for analysis of serum COMP should be drawn after at least 30 minutes rest in a seated position. No increase was seen after a six-week exercise program indicating that any effect of individualized supervised exercise on cartilage turnover is transient.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="6416" xml_f="6426" txt_i="2187" txt_f="2197">Background</offsets></title><p><offsets xml_i="6437" xml_f="6607" txt_i="2198" txt_f="2368">Osteoarthritis (OA) is a disorder of multifactorial origin, which involves articular cartilage, synovium, subchondral bone, ligaments and/or the neuromuscular apparatus [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="6638" xml_f="6639" txt_i="2368" txt_f="2369">1</offsets></xref><offsets xml_i="6646" xml_f="6858" txt_i="2369" txt_f="2581">]. OA causes disability, pain and reduced quality of life. Risk factors for occurrence and progression of knee OA include age, previous injury, increased body mass index (BMI), genetic factors and high workload [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="6889" xml_f="6890" txt_i="2581" txt_f="2582">2</offsets></xref><offsets xml_i="6897" xml_f="7009" txt_i="2582" txt_f="2694">]. Studies suggest that low quadriceps strength increases the risk of OA development in the tibiofemoral joint [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="7040" xml_f="7041" txt_i="2694" txt_f="2695">3</offsets></xref><offsets xml_i="7048" xml_f="7096" txt_i="2695" txt_f="2743">]. Exercise is recommended for treatment of OA [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="7127" xml_f="7128" txt_i="2743" txt_f="2744">4</offsets></xref><offsets xml_i="7135" xml_f="7254" txt_i="2744" txt_f="2863">]. Several studies have shown that increased muscle strength provides joint stability and reduces pain and disability [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="7285" xml_f="7286" txt_i="2863" txt_f="2864">5</offsets></xref><offsets xml_i="7293" xml_f="7294" txt_i="2864" txt_f="2865">-</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="7325" xml_f="7326" txt_i="2865" txt_f="2866">7</offsets></xref><offsets xml_i="7333" xml_f="7429" txt_i="2866" txt_f="2962">]. It is not clear if physical exercise also affects the properties of joint cartilage in vivo [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="7460" xml_f="7461" txt_i="2962" txt_f="2963">8</offsets></xref><offsets xml_i="7468" xml_f="7668" txt_i="2963" txt_f="3163">]. However, a recent study using delayed gadolinium enhanced magnetic resonance imaging in patients at high risk of knee OA, suggested increased glycosaminoglycan content in cartilage after exercise [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="7699" xml_f="7700" txt_i="3163" txt_f="3164">9</offsets></xref><offsets xml_i="7707" xml_f="7828" txt_i="3164" txt_f="3285">]. In vitro studies have shown enhanced production of matrix components in cartilage explants during cyclic compression [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="7860" xml_f="7862" txt_i="3285" txt_f="3287">10</offsets></xref><offsets xml_i="7869" xml_f="7870" txt_i="3287" txt_f="3288">,</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="7902" xml_f="7904" txt_i="3288" txt_f="3290">11</offsets></xref><offsets xml_i="7911" xml_f="7913" txt_i="3290" txt_f="3292">].</offsets></p><p><offsets xml_i="7920" xml_f="8050" txt_i="3293" txt_f="3423">A possible way to identify tissue matrix processes in OA is by monitoring tissue proteins or their fragments released into serum [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="8082" xml_f="8084" txt_i="3423" txt_f="3425">12</offsets></xref><offsets xml_i="8091" xml_f="8092" txt_i="3425" txt_f="3426">,</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="8124" xml_f="8126" txt_i="3426" txt_f="3428">13</offsets></xref><offsets xml_i="8133" xml_f="8234" txt_i="3428" txt_f="3529">]. Such biomarkers also represent potential tools for monitoring effects of treatment on the tissue [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="8266" xml_f="8268" txt_i="3529" txt_f="3531">14</offsets></xref><offsets xml_i="8275" xml_f="8441" txt_i="3531" txt_f="3697">]. One such potential biomarker is cartilage oligomeric matrix protein (COMP). COMP is a five-armed 435 kD non-collagenous protein primarily identified in cartilage [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="8473" xml_f="8475" txt_i="3697" txt_f="3699">15</offsets></xref><offsets xml_i="8482" xml_f="8483" txt_i="3699" txt_f="3700">,</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="8515" xml_f="8517" txt_i="3700" txt_f="3702">16</offsets></xref><offsets xml_i="8524" xml_f="8692" txt_i="3702" txt_f="3870">]. COMP interacts with collagen and is suggested to have a role in regulating fibril assembly as well as a structural role for maintaining the mature collagen network [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="8724" xml_f="8726" txt_i="3870" txt_f="3872">17</offsets></xref><offsets xml_i="8733" xml_f="8869" txt_i="3872" txt_f="4008">]. Studies of experimental arthritis have been used to demonstrate that changes in serum levels of COMP reflect processes in cartilage [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="8901" xml_f="8903" txt_i="4008" txt_f="4010">18</offsets></xref><offsets xml_i="8910" xml_f="8911" txt_i="4010" txt_f="4011">,</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="8943" xml_f="8945" txt_i="4011" txt_f="4013">19</offsets></xref><offsets xml_i="8952" xml_f="9195" txt_i="4013" txt_f="4256">]. Supportive evidence from human arthritis is also emerging. For instance, therapeutic interventions which aim at retarding joint damage, such as blockade of tumour necrosis factor- alpha in rheumatoid arthritis, normalize serum COMP levels [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="9227" xml_f="9229" txt_i="4256" txt_f="4258">20</offsets></xref><offsets xml_i="9236" xml_f="9434" txt_i="4258" txt_f="4456">]. In other studies, the feasibility of serum COMP as a prognostic indicator of future joint damage and as a marker of ongoing joint damage, e.g. in OA and rheumatoid arthritis, has been suggested [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="9466" xml_f="9468" txt_i="4456" txt_f="4458">21</offsets></xref><offsets xml_i="9475" xml_f="9476" txt_i="4458" txt_f="4459">-</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="9508" xml_f="9510" txt_i="4459" txt_f="4461">24</offsets></xref><offsets xml_i="9517" xml_f="9702" txt_i="4461" txt_f="4646">]. Thus, although small amounts of COMP are present in other tissues i.e. tendon and synovium, the evidence in favour of serum COMP being primarily derived from cartilage is compelling.</offsets></p><p><offsets xml_i="9709" xml_f="9917" txt_i="4647" txt_f="4855">The objective of the present intervention was to monitor serum concentrations of COMP in a randomised controlled trial of physical exercise in patients with symptomatic and radiographically verified knee OA [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="9949" xml_f="9951" txt_i="4855" txt_f="4857">25</offsets></xref><offsets xml_i="9958" xml_f="10166" txt_i="4857" txt_f="5065">] to elucidate how standardised physical activity influences the turnover of COMP, study 1. In a supplementary small study we examined the short-term changes of serum-COMP immediately after exercise, study 2.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="10207" xml_f="10214" txt_i="5067" txt_f="5074">Methods</offsets></title><sec><title><offsets xml_i="10234" xml_f="10242" txt_i="5075" txt_f="5083">Subjects</offsets></title><p><offsets xml_i="10253" xml_f="10541" txt_i="5084" txt_f="5372">In study 1 patients aged 36–65 years with symptomatic radiographically verified knee OA, uni- or bilateral Kellgren-Lawrence grade 3 or more, were included in a randomised controlled trial of physical exercise in knee OA. The clinical results of this study have previously been reported [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="10573" xml_f="10575" txt_i="5372" txt_f="5374">25</offsets></xref><offsets xml_i="10582" xml_f="10794" txt_i="5374" txt_f="5586">]. Patients were recruited from the Department of Radiology at the Halmstad County Hospital in Sweden. They had been referred to radiographic knee joint examination due to knee pain by their general practitioner.</offsets></p><p><offsets xml_i="10801" xml_f="11623" txt_i="5587" txt_f="6409">Patients with inflammatory joint disorders, previous anterior cruciate ligament injury, or known injury to the menisci were excluded. Furthermore, patients with hip symptoms more severe than the knee symptoms (verified by clinical examination), patients being on the waiting list for knee replacement expected to be operated within 6 months, or with co-morbidities not allowing exercise were also excluded. Fifty-eight subjects fulfilled the criteria for inclusion and were randomised to exercise (n = 29,15 men and 14 women, with median (range) age 55 years (36–64) and median (range) Body Mass Index (BMI) 28.7 (23.0–43.0)) or rest (n = 29, 14 men and 15 women with median (range) age 57 years (46–65) and median (range) BMI 27.9 (22.0–45.0). The exercise group and the control group did not differ regarding age or BMI.</offsets></p><p><offsets xml_i="11630" xml_f="12205" txt_i="6410" txt_f="6985">Blood samples were obtained from all subjects at predefined intervals. At each occasion blood samples were obtained twice with an hour apart, in total 8 samples during study 1. Samples were taken at four different occasions, before intervention at -3 weeks, during intervention at two time points, 0 and 6 weeks, and after intervention at 24 weeks. At weeks -3 and 24 both groups were resting for one hour and at weeks 0 and 6 the exercise group was exercising and the control group was resting one hour between sampling of blood. The sampling schedule is outlined in figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="12235" xml_f="12236" txt_i="6985" txt_f="6986">1</offsets></xref><offsets xml_i="12243" xml_f="12244" txt_i="6986" txt_f="6987">.</offsets></p><p><offsets xml_i="12251" xml_f="12882" txt_i="6988" txt_f="7619">All patients in the exercise group followed the exercise protocol. The program consisted of weight-bearing exercises aimed at increasing postural control, endurance and strength in the lower extremity. Exercises were performed at five stations at intensity of ≥ 60% of maximum heart rate (HRmax). This one-hour supervised, high intensity session was performed twice a week increasing aerobic capacity and muscular endurance and strength in the lower extremities. Home exercises for at least 30 minutes every day were prescribed for the other days during the six-week intervention period. The protocol has been described in detail [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="12914" xml_f="12916" txt_i="7619" txt_f="7621">25</offsets></xref><offsets xml_i="12923" xml_f="12925" txt_i="7621" txt_f="7623">].</offsets></p><p><offsets xml_i="12932" xml_f="13269" txt_i="7624" txt_f="7961">The control group had no restrictions and were instructed to continue with their usual daily activities. All patients had been travelling to the hospital and there was no standardised rest period before the first serum sample was drawn. The control group was resting in a chair for one hour between the blood sampling procedures, figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="13299" xml_f="13300" txt_i="7961" txt_f="7962">1</offsets></xref><offsets xml_i="13307" xml_f="13308" txt_i="7962" txt_f="7963">.</offsets></p><p><offsets xml_i="13315" xml_f="14072" txt_i="7964" txt_f="8721">We also designed a second, supplementary study to monitor serum COMP with repeated measurements after the exercise session. Seven patients, who had participated in the exercise-group in the first study, median (range) age 55 years (51–67) and median (range) BMI 27.2 (24.9–37.5) were included. The physical exercise consisted of a one-hour supervised, high intensity session, as performed in study 1. Blood samples were collected before, immediately after, 30 and 60 minutes after the exercise session and then with 60 minutes interval for another five hours. The patients were told not to exercise 24 hours before sampling. After the training session they were resting in a chair in the hospital waiting room until the last serum sample had been retrieved.</offsets></p></sec><sec><title><offsets xml_i="14094" xml_f="14107" txt_i="8723" txt_f="8736">COMP analyses</offsets></title><p><offsets xml_i="14118" xml_f="14508" txt_i="8737" txt_f="9127">Venous blood samples were obtained from vena mediana cubitii. After clotting for 60 minutes at room temperature, they were centrifuged at 2000 g for 10 minutes at +4°C. The serum samples were stored at -20°C until all the serum samples were obtained. The samples were then stored at -80°C until analysis. Serum COMP levels were analysed with a sandwich-ELISA (AnaMar Medical, Lund, Sweden).</offsets></p></sec><sec><title><offsets xml_i="14530" xml_f="14570" txt_i="9129" txt_f="9169">Statistical methods and ethical approval</offsets></title><p><offsets xml_i="14581" xml_f="14988" txt_i="9170" txt_f="9574">Comparisons between groups and within groups were performed using Mann-Whitney U test and Wilcoxon matched pairs test, respectively. A p-value of &lt;0.05 was considered significant. Informed consent was obtained from the patients participating in the study. Ethical approval was obtained from the Research Ethics Committee, Lund University, Sweden (LU 99–98) and is in compliance with Helsinki Declaration.</offsets></p></sec></sec><sec><title><offsets xml_i="15016" xml_f="15023" txt_i="9577" txt_f="9584">Results</offsets></title><sec><title><offsets xml_i="15043" xml_f="15050" txt_i="9585" txt_f="9592">Study 1</offsets></title><sec><title><offsets xml_i="15070" xml_f="15101" txt_i="9593" txt_f="9624">1. Serum COMP at start of study</offsets></title><p><offsets xml_i="15112" xml_f="15527" txt_i="9625" txt_f="10037">At time point -3 weeks, i.e. three weeks before the intervention started, there were no significant differences in serum COMP levels between the exercise and control group. Median (range) serum COMP levels were in the exercise-group 11.03 (6.60–16.52) U/L and in the control-group 11.29 (6.38–22.11) U/L. In both groups there was a slight decrease in serum-COMP levels after one hour of rest (p &lt; 0.001), figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="15557" xml_f="15558" txt_i="10037" txt_f="10038">2</offsets></xref><offsets xml_i="15565" xml_f="15566" txt_i="10038" txt_f="10039">.</offsets></p></sec><sec><title><offsets xml_i="15588" xml_f="15621" txt_i="10041" txt_f="10074">2. Serum COMP during intervention</offsets></title><p><offsets xml_i="15632" xml_f="15906" txt_i="10075" txt_f="10346">Before exercise no significant differences in COMP levels were seen between the two groups at 0 or at 6 weeks, data not shown. After 60 minutes of exercise serum COMP levels increased (median increase 1.3 U/L, p &lt; 0.001) at both time points in the exercise group, figure </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="15936" xml_f="15937" txt_i="10346" txt_f="10347">3</offsets></xref><offsets xml_i="15944" xml_f="16112" txt_i="10347" txt_f="10515">. At time point 0 and 6 the serum levels decreased slightly after one hour rest in the control group (median decrease 0.6 U/L, p = 0.003 and p = 0.053), data not shown.</offsets></p></sec><sec><title><offsets xml_i="16134" xml_f="16188" txt_i="10517" txt_f="10571">3. Serum COMP during the study period and at follow up</offsets></title><p><offsets xml_i="16199" xml_f="16819" txt_i="10572" txt_f="11192">At time point 24 weeks, serum COMP levels decreased after one hour of rest in both groups, p = 0.002 in exercise group and p = 0.004 in control group, in a similar manner as at time point – 3 weeks. Serum COMP values did not differ between start (-3 weeks) and end of the study (24 weeks) in either group (data not shown). Thus the levels returned to baseline after the dynamic exercise intervention and after resting. Median (range) serum COMP levels were at the end of the study 10.92 (7.43–15.98) U/L in the exercise-group and 11.24 (7.28–22.00) U/L in the control group. The levels did not differ between the groups.</offsets></p></sec></sec><sec><title><offsets xml_i="16847" xml_f="16854" txt_i="11195" txt_f="11202">Study 2</offsets></title><sec><title><offsets xml_i="16874" xml_f="16975" txt_i="11203" txt_f="11304">Serum COMP after standardised exercise in seven patients recruited from the exercise group in study 1</offsets></title><p><offsets xml_i="16986" xml_f="17285" txt_i="11305" txt_f="11604">Blood samples were collected before, immediately after, 30 and 60 minutes after the exercise session and then with 60 minutes interval for another five hours. The serum COMP levels increased immediately after exercise from a median level of 10.5 U/L to a median level of 11.6 U/L, p = 0.018, figure </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="17315" xml_f="17316" txt_i="11604" txt_f="11605">4</offsets></xref><offsets xml_i="17323" xml_f="17469" txt_i="11605" txt_f="11751">. The levels then decreased and at 30 minutes after the exercise session the levels did not differ significantly from baseline. As seen in figure </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="17499" xml_f="17500" txt_i="11751" txt_f="11752">4</offsets></xref><offsets xml_i="17507" xml_f="17612" txt_i="11752" txt_f="11857"> insert, the median level tended to decrease towards baseline levels during the whole observation period.</offsets></p></sec></sec></sec><sec><title><offsets xml_i="17646" xml_f="17656" txt_i="11861" txt_f="11871">Discussion</offsets></title><p><offsets xml_i="17667" xml_f="18462" txt_i="11872" txt_f="12667">In this study of patients with knee OA, we could in a reproducible fashion show that physical activity according to a predefined protocol resulted in a significant increase in the serum levels of COMP. In contrast, resting in a chair for one hour reduced the serum levels slightly, but significantly. We did not observe any changes of the baseline COMP levels over the 24-week period, thus there appears to be no long-term influence on the turnover of COMP induced by this physical exercise. To further examine the changes in serum COMP after exercise we performed a supplementary study with more frequent measurements to elucidate the kinetics of serum COMP during the time immediately following the exercise session. We found that the serum concentrations rapidly returned to baseline, figure </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="18492" xml_f="18493" txt_i="12667" txt_f="12668">4</offsets></xref><offsets xml_i="18500" xml_f="18576" txt_i="12668" txt_f="12744">, and the concentrations did not differ from baseline after 30-minutes rest.</offsets></p><p><offsets xml_i="18583" xml_f="18794" txt_i="12745" txt_f="12956">Recently Mündermann and co-workers reported that moderate walking activity during 30 minutes in healthy individuals significantly increased serum COMP as measured by the same assay as the one used in our study [</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="18826" xml_f="18828" txt_i="12956" txt_f="12958">26</offsets></xref><offsets xml_i="18835" xml_f="19120" txt_i="12958" txt_f="13243">]. Importantly, in line with the results in the OA patients in the present study, they found that the serum levels had returned to baseline after 30 minutes. They also found that serum COMP decreased during rest in these individuals, also in line with the results of the present study.</offsets></p><p><offsets xml_i="19127" xml_f="19553" txt_i="13244" txt_f="13670">Neidhart and co-workers found increasing serum levels of COMP using another assay in 8 athletes during a marathon run. In these endurance-trained runners serum COMP was at baseline elevated compared to healthy age- and sex-matched controls. The serum levels returned to baseline within 24–48 hours, which was considerably slower than in our study possibly because of more extreme exercise in these physically fit individuals [</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="19585" xml_f="19587" txt_i="13670" txt_f="13672">27</offsets></xref><offsets xml_i="19594" xml_f="19596" txt_i="13672" txt_f="13674">].</offsets></p><p><offsets xml_i="19603" xml_f="19970" txt_i="13675" txt_f="14042">One possible reason for the changes in serum COMP during physical exercise is mobilization of COMP from cartilage or other pressure loaded tissues. Increased cartilage degradation without compensatory increased synthesis cannot be ruled out. However, since the changes are transient it is unlikely that the exercise exerts any negative long-term effects on cartilage.</offsets></p><p><offsets xml_i="19977" xml_f="20251" txt_i="14043" txt_f="14317">Another, perhaps more likely reason for the changes could be modifications of the extra-cartilage turnover of COMP with more of the protein being transported from the synovial fluid into the lymphatics and further into the blood stream during and immediately after exercise.</offsets></p><p><offsets xml_i="20258" xml_f="20518" txt_i="14318" txt_f="14578">We have in another study shown a diurnal variation of serum COMP with stable levels during daytime and with the lowest levels found at night during bed rest. This is in line with the results of the present study where decreasing levels were found during rest [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="20550" xml_f="20552" txt_i="14578" txt_f="14580">28</offsets></xref><offsets xml_i="20559" xml_f="20667" txt_i="14580" txt_f="14688">]. In the study of diurnal variation a putitative half-life of COMP in serum was calculated to be 7.4 hours.</offsets></p><p><offsets xml_i="20674" xml_f="20933" txt_i="14689" txt_f="14948">All patients had been travelling to the hospital and there was no standardised rest period before the first serum sample was drawn. This could mean that the observed decrease of serum levels during rest was due to a return to baseline after physical activity.</offsets></p></sec><sec><title><offsets xml_i="20955" xml_f="20965" txt_i="14950" txt_f="14960">Conclusion</offsets></title><p><offsets xml_i="20976" xml_f="21848" txt_i="14961" txt_f="15833">The changes in serum levels of COMP, are small and do not compromise the utility of COMP as a biomarker, e.g. for monitoring treatment effects on the tissue. Thus, we suggest that samples of blood for analysis of serum COMP should be drawn after at least 30 minutes rest in a seated position. This is particularly important if sequential samples are to be obtained from the same patient. It should be noted that the information provided in this study pertains to patients with knee OA. However, since similar findings were reported for healthy controls it seems reasonable to adhere to this recommendation for all patients. Finally, it should be stressed that little information regarding the influence of exercise on serum concentrations for other putative biomarkers of cartilage is available. Thus, we suggest that similar studies should be performed for other markers.</offsets></p></sec><sec><title><offsets xml_i="21870" xml_f="21883" txt_i="15835" txt_f="15848">Abbreviations</offsets></title><p><offsets xml_i="21894" xml_f="21934" txt_i="15849" txt_f="15889">COMP Cartilage oligomeric matrix protein</offsets></p><p><offsets xml_i="21941" xml_f="21980" txt_i="15890" txt_f="15929">ELISA Enzyme-linked immunosorbent assay</offsets></p><p><offsets xml_i="21987" xml_f="22004" txt_i="15930" txt_f="15947">OA Osteoarthritis</offsets></p><p><offsets xml_i="22011" xml_f="22030" txt_i="15948" txt_f="15967">BMI Body mass index</offsets></p><p><offsets xml_i="22037" xml_f="22061" txt_i="15968" txt_f="15992">HRmax Maximum heart rate</offsets></p></sec><sec><title><offsets xml_i="22083" xml_f="22102" txt_i="15994" txt_f="16013">Competing interests</offsets></title><p><offsets xml_i="22113" xml_f="22216" txt_i="16014" txt_f="16117">DH and TS are cofounders and shareholders in AnaMar Medical and IP is a board member of AnaMar Medical.</offsets></p></sec><sec><title><offsets xml_i="22238" xml_f="22260" txt_i="16119" txt_f="16141">Authors' contributions</offsets></title><p><offsets xml_i="22271" xml_f="22428" txt_i="16142" txt_f="16299">MA took part in the design of this study, in the blood sampling, carried out the COMP-analyse, performed the statistical analysis and drafted the manuscript.</offsets></p><p><offsets xml_i="22435" xml_f="22548" txt_i="16300" txt_f="16413">CT participated in the design of the study, coordinated the clinical parts and carried out the physical training.</offsets></p><p><offsets xml_i="22555" xml_f="22615" txt_i="16414" txt_f="16474">ER participated in the design and coordination of the study.</offsets></p><p><offsets xml_i="22622" xml_f="22739" txt_i="16475" txt_f="16592">IP participated in the design of the study, helped in the statistical discussions and helped drafting the manuscript.</offsets></p><p><offsets xml_i="22746" xml_f="22829" txt_i="16593" txt_f="16676">DH participated in the design of the study and assisted in drafting the manuscript.</offsets></p><p><offsets xml_i="22836" xml_f="22953" txt_i="16677" txt_f="16794">TS participated in the design of the study, helped in the statistical discussions and helped drafting the manuscript.</offsets></p><p><offsets xml_i="22960" xml_f="23010" txt_i="16795" txt_f="16845">All authors read and approved the final manuscript</offsets></p></sec><sec><title><offsets xml_i="23032" xml_f="23055" txt_i="16847" txt_f="16870">Pre-publication history</offsets></title><p><offsets xml_i="23066" xml_f="23130" txt_i="16871" txt_f="16935">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2474/7/98/prepub"></ext-link></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The Swedish Medical Research Council, NIAMS, National Institute of Health Grant U01-AR050926, King Gustaf V 80-year Found, The Swedish Rheumatism Association, Spenshult's Research Foundations, the Österlund and the Kock Foundations for supporting by grants.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Brandt</surname><given-names>K</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name><name><surname>Lohmander</surname><given-names>S</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Brandt KDM, Lohmander S</surname></name></person-group><article-title>Pathogenesis of osteoarthritis – Introduction</article-title><source>Osteoarthritis</source><year>1998</year><publisher-name>Oxford: Oxford University Press</publisher-name><fpage>70</fpage><lpage>73</lpage></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petersson</surname><given-names>IF</given-names></name><name><surname>Jacobsson</surname><given-names>LT</given-names></name></person-group><article-title>Osteoarthritis of the peripheral joints</article-title><source>Best Pract Res Clin Rheumatol</source><year>2002</year><volume>16</volume><fpage>741</fpage><lpage>760</lpage><pub-id pub-id-type="pmid">12473271</pub-id><pub-id pub-id-type="doi">10.1053/berh.2002.0266</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thorstensson</surname><given-names>CA</given-names></name><name><surname>Petersson</surname><given-names>IF</given-names></name><name><surname>Jacobsson</surname><given-names>LT</given-names></name><name><surname>Boegard</surname><given-names>TL</given-names></name><name><surname>Roos</surname><given-names>EM</given-names></name></person-group><article-title>Reduced functional performance in the lower extremity predicted radiographic knee osteoarthritis five years later</article-title><source>Ann Rheum Dis</source><year>2004</year><volume>63</volume><fpage>402</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">15020334</pub-id><pub-id pub-id-type="doi">10.1136/ard.2003.007583</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>KM</given-names></name><name><surname>Arden</surname><given-names>NK</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name><name><surname>Bannwarth</surname><given-names>B</given-names></name><name><surname>Bijlsma</surname><given-names>JW</given-names></name><name><surname>Dieppe</surname><given-names>P</given-names></name><name><surname>Gunther</surname><given-names>K</given-names></name><name><surname>Hauselmann</surname><given-names>H</given-names></name><name><surname>Herrero-Beaumont</surname><given-names>G</given-names></name><name><surname>Kaklamanis</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)</article-title><source>Ann Rheum Dis</source><year>2003</year><volume>62</volume><fpage>1145</fpage><lpage>1155</lpage><pub-id pub-id-type="pmid">14644851</pub-id><pub-id pub-id-type="doi">10.1136/ard.2003.011742</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ettinger</surname><given-names>WH</given-names><suffix>Jr</suffix></name><name><surname>Burns</surname><given-names>R</given-names></name><name><surname>Messier</surname><given-names>SP</given-names></name><name><surname>Applegate</surname><given-names>W</given-names></name><name><surname>Rejeski</surname><given-names>WJ</given-names></name><name><surname>Morgan</surname><given-names>T</given-names></name><name><surname>Shumaker</surname><given-names>S</given-names></name><name><surname>Berry</surname><given-names>MJ</given-names></name><name><surname>O'Toole</surname><given-names>M</given-names></name><name><surname>Monu</surname><given-names>J</given-names></name><name><surname>Craven</surname><given-names>T</given-names></name></person-group><article-title>A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis. The Fitness Arthritis and Seniors Trial (FAST)</article-title><source>JAMA</source><year>1997</year><volume>277</volume><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">8980206</pub-id><pub-id pub-id-type="doi">10.1001/jama.277.1.25</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rogind</surname><given-names>H</given-names></name><name><surname>Bibow-Nielsen</surname><given-names>B</given-names></name><name><surname>Jensen</surname><given-names>B</given-names></name><name><surname>Moller</surname><given-names>HC</given-names></name><name><surname>Frimodt-Moller</surname><given-names>H</given-names></name><name><surname>Bliddal</surname><given-names>H</given-names></name></person-group><article-title>The effects of a physical training program on patients with osteoarthritis of the knees</article-title><source>Arch Phys Med Rehabil</source><year>1998</year><volume>79</volume><fpage>1421</fpage><lpage>1427</lpage><pub-id pub-id-type="pmid">9821904</pub-id><pub-id pub-id-type="doi">10.1016/S0003-9993(98)90238-6</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deyle</surname><given-names>GD</given-names></name><name><surname>Henderson</surname><given-names>NE</given-names></name><name><surname>Matekel</surname><given-names>RL</given-names></name><name><surname>Ryder</surname><given-names>MG</given-names></name><name><surname>Garber</surname><given-names>MB</given-names></name><name><surname>Allison</surname><given-names>SC</given-names></name></person-group><article-title>Effectiveness of manual physical therapy and exercise in osteoarthritis of the knee. A randomized, controlled trial</article-title><source>Ann Intern Med</source><year>2000</year><volume>132</volume><fpage>173</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">10651597</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roos</surname><given-names>H</given-names></name><name><surname>Dahlberg</surname><given-names>L</given-names></name><name><surname>Hoerrner</surname><given-names>LA</given-names></name><name><surname>Lark</surname><given-names>MW</given-names></name><name><surname>Thonar</surname><given-names>EJ</given-names></name><name><surname>Shinmei</surname><given-names>M</given-names></name><name><surname>Lindqvist</surname><given-names>U</given-names></name><name><surname>Lohmander</surname><given-names>LS</given-names></name></person-group><article-title>Markers of cartilage matrix metabolism in human joint fluid and serum: the effect of exercise</article-title><source>Osteoarthritis Cartilage</source><year>1995</year><volume>3</volume><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">7719956</pub-id><pub-id pub-id-type="doi">10.1016/S1063-4584(05)80033-0</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roos</surname><given-names>EM</given-names></name><name><surname>Dahlberg</surname><given-names>L</given-names></name></person-group><article-title>Positive effects of moderate exercise on glycosaminoglycan content in knee cartilage: A four-month, randomized, controlled trial in patients at risk of osteoarthritis</article-title><source>Arthritis Rheum</source><year>2005</year><volume>52</volume><fpage>3507</fpage><lpage>3514</lpage><pub-id pub-id-type="pmid">16258919</pub-id><pub-id pub-id-type="doi">10.1002/art.21415</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giannoni</surname><given-names>P</given-names></name><name><surname>Siegrist</surname><given-names>M</given-names></name><name><surname>Hunziker</surname><given-names>EB</given-names></name><name><surname>Wong</surname><given-names>M</given-names></name></person-group><article-title>The mechanosensitivity of cartilage oligomeric matrix protein (COMP)</article-title><source>Biorheology</source><year>2003</year><volume>40</volume><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">12454393</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>M</given-names></name><name><surname>Siegrist</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><article-title>Cyclic compression of articular cartilage explants is associated with progressive consolidation and altered expression pattern of extracellular matrix proteins</article-title><source>Matrix Biol</source><year>1999</year><volume>18</volume><fpage>391</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">10517186</pub-id><pub-id pub-id-type="doi">10.1016/S0945-053X(99)00029-3</pub-id></citation></ref><ref id="B12"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Saxne</surname><given-names>T</given-names></name><name><surname>Månsson</surname><given-names>B</given-names></name><name><surname>Heinegård</surname><given-names>D</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Firestein GS, Panayi GS, Wollheim FA</surname></name></person-group><article-title>Molecular markers for assessment of cartilage damage in rheumatoid arthritis</article-title><source>Rheumatoid Arthritis</source><year>2006</year><edition>2</edition><publisher-name>New York: Oxford University Press</publisher-name><fpage>301</fpage><lpage>316</lpage></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poole</surname><given-names>AR</given-names></name></person-group><article-title>Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis</article-title><source>Rheum Dis Clin North Am</source><year>2003</year><volume>29</volume><fpage>803</fpage><lpage>818</lpage><pub-id pub-id-type="pmid">14603584</pub-id><pub-id pub-id-type="doi">10.1016/S0889-857X(03)00056-5</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kraus</surname><given-names>VB</given-names></name></person-group><article-title>Biomarkers in osteoarthritis</article-title><source>Curr Opin Rheumatol</source><year>2005</year><volume>17</volume><fpage>641</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">16093846</pub-id><pub-id pub-id-type="doi">10.1097/01.bor.0000174195.15421.17</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hedbom</surname><given-names>E</given-names></name><name><surname>Antonsson</surname><given-names>P</given-names></name><name><surname>Hjerpe</surname><given-names>A</given-names></name><name><surname>Aeschlimann</surname><given-names>D</given-names></name><name><surname>Paulsson</surname><given-names>M</given-names></name><name><surname>Rosa-Pimentel</surname><given-names>E</given-names></name><name><surname>Sommarin</surname><given-names>Y</given-names></name><name><surname>Wendel</surname><given-names>M</given-names></name><name><surname>Oldberg</surname><given-names>A</given-names></name><name><surname>Heinegard</surname><given-names>D</given-names></name></person-group><article-title>Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage</article-title><source>J Biol Chem</source><year>1992</year><volume>267</volume><fpage>6132</fpage><lpage>6136</lpage><pub-id pub-id-type="pmid">1556121</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saxne</surname><given-names>T</given-names></name><name><surname>Heinegard</surname><given-names>D</given-names></name></person-group><article-title>Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood</article-title><source>Br J Rheumatol</source><year>1992</year><volume>31</volume><fpage>583</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">1381980</pub-id></citation></ref><ref id="B17"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Heinegård</surname><given-names>D</given-names></name><name><surname>Lorenzo</surname><given-names>P</given-names></name><name><surname>Saxne</surname><given-names>T</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Harris ED, Budd RC, Firestein GS, Genovese MC, Ruddy S</surname></name></person-group><article-title>Matrix Glycoproteins and Proteoglycans in Cartilage</article-title><source>Kelley's Textbook of Rheumatology</source><year>2005</year><publisher-name>Philadelphia: Elsevier Saunders</publisher-name><fpage>48</fpage><lpage>62</lpage></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Erlandsson Harris</surname><given-names>H</given-names></name><name><surname>Lorentzen</surname><given-names>JC</given-names></name><name><surname>Larsson</surname><given-names>A</given-names></name><name><surname>Mansson</surname><given-names>B</given-names></name><name><surname>Klareskog</surname><given-names>L</given-names></name><name><surname>Saxne</surname><given-names>T</given-names></name></person-group><article-title>Serum concentrations of cartilage oligomeric matrix protein, fibrinogen and hyaluronan distinguish inflammation and cartilage destruction in experimental arthritis in rats</article-title><source>Rheumatology (Oxford)</source><year>2002</year><volume>41</volume><fpage>996</fpage><lpage>1000</lpage><pub-id pub-id-type="pmid">12209032</pub-id><pub-id pub-id-type="doi">10.1093/rheumatology/41.9.996</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Erlandsson Harris</surname><given-names>H</given-names></name><name><surname>Larsson</surname><given-names>A</given-names></name><name><surname>Mansson</surname><given-names>B</given-names></name><name><surname>Saxne</surname><given-names>T</given-names></name><name><surname>Klareskog</surname><given-names>L</given-names></name></person-group><article-title>Corticosteroid treatment of experimental arthritis retards cartilage destruction as determined by histology and serum COMP</article-title><source>Rheumatology (Oxford)</source><year>2004</year><volume>43</volume><fpage>428</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">15024132</pub-id><pub-id pub-id-type="doi">10.1093/rheumatology/keh073</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crnkic</surname><given-names>M</given-names></name><name><surname>Mansson</surname><given-names>B</given-names></name><name><surname>Larsson</surname><given-names>L</given-names></name><name><surname>Geborek</surname><given-names>P</given-names></name><name><surname>Heinegard</surname><given-names>D</given-names></name><name><surname>Saxne</surname><given-names>T</given-names></name></person-group><article-title>Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept</article-title><source>Arthritis Res Ther</source><year>2003</year><volume>5</volume><fpage>R181</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">12823852</pub-id><pub-id pub-id-type="doi">10.1186/ar760</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petersson</surname><given-names>IF</given-names></name><name><surname>Boegard</surname><given-names>T</given-names></name><name><surname>Svensson</surname><given-names>B</given-names></name><name><surname>Heinegard</surname><given-names>D</given-names></name><name><surname>Saxne</surname><given-names>T</given-names></name></person-group><article-title>Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint</article-title><source>Br J Rheumatol</source><year>1998</year><volume>37</volume><fpage>46</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">9487250</pub-id><pub-id pub-id-type="doi">10.1093/rheumatology/37.1.46</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mansson</surname><given-names>B</given-names></name><name><surname>Carey</surname><given-names>D</given-names></name><name><surname>Alini</surname><given-names>M</given-names></name><name><surname>Ionescu</surname><given-names>M</given-names></name><name><surname>Rosenberg</surname><given-names>LC</given-names></name><name><surname>Poole</surname><given-names>AR</given-names></name><name><surname>Heinegard</surname><given-names>D</given-names></name><name><surname>Saxne</surname><given-names>T</given-names></name></person-group><article-title>Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism</article-title><source>J Clin Invest</source><year>1995</year><volume>95</volume><fpage>1071</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">7533784</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharif</surname><given-names>M</given-names></name><name><surname>Kirwan</surname><given-names>JR</given-names></name><name><surname>Elson</surname><given-names>CJ</given-names></name><name><surname>Granell</surname><given-names>R</given-names></name><name><surname>Clarke</surname><given-names>S</given-names></name></person-group><article-title>Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years</article-title><source>Arthritis Rheum</source><year>2004</year><volume>50</volume><fpage>2479</fpage><lpage>2488</lpage><pub-id pub-id-type="pmid">15334461</pub-id><pub-id pub-id-type="doi">10.1002/art.20365</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindqvist</surname><given-names>E</given-names></name><name><surname>Eberhardt</surname><given-names>K</given-names></name><name><surname>Bendtzen</surname><given-names>K</given-names></name><name><surname>Heinegard</surname><given-names>D</given-names></name><name><surname>Saxne</surname><given-names>T</given-names></name></person-group><article-title>Prognostic laboratory markers of joint damage in rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><year>2005</year><volume>64</volume><fpage>196</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">15458956</pub-id><pub-id pub-id-type="doi">10.1136/ard.2003.019992</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thorstensson</surname><given-names>CA</given-names></name><name><surname>Roos</surname><given-names>EM</given-names></name><name><surname>Petersson</surname><given-names>IF</given-names></name><name><surname>Ekdahl</surname><given-names>C</given-names></name></person-group><article-title>Six-week high-intensity exercise program for middle-aged patients with knee osteoarthritis: a randomized controlled trial [ISRCTN20244858]</article-title><source>BMC Musculoskelet Disord</source><year>2005</year><volume>6</volume><fpage>27</fpage><pub-id pub-id-type="pmid">15924620</pub-id><pub-id pub-id-type="doi">10.1186/1471-2474-6-27</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mundermann</surname><given-names>A</given-names></name><name><surname>Dyrby</surname><given-names>CO</given-names></name><name><surname>Andriacchi</surname><given-names>TP</given-names></name><name><surname>King</surname><given-names>KB</given-names></name></person-group><article-title>Serum concentration of cartilage oligomeric matrix protein (COMP) is sensitive to physiological cyclic loading in healthy adults</article-title><source>Osteoarthritis Cartilage</source><year>2005</year><volume>13</volume><fpage>34</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">15639635</pub-id><pub-id pub-id-type="doi">10.1016/j.joca.2004.09.007</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neidhart</surname><given-names>M</given-names></name><name><surname>Muller-Ladner</surname><given-names>U</given-names></name><name><surname>Frey</surname><given-names>W</given-names></name><name><surname>Bosserhoff</surname><given-names>AK</given-names></name><name><surname>Colombani</surname><given-names>PC</given-names></name><name><surname>Frey-Rindova</surname><given-names>P</given-names></name><name><surname>Hummel</surname><given-names>KM</given-names></name><name><surname>Gay</surname><given-names>RE</given-names></name><name><surname>Hauselmann</surname><given-names>H</given-names></name><name><surname>Gay</surname><given-names>S</given-names></name></person-group><article-title>Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners</article-title><source>Osteoarthritis Cartilage</source><year>2000</year><volume>8</volume><fpage>222</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">10806050</pub-id><pub-id pub-id-type="doi">10.1053/joca.1999.0293</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>ML</given-names></name><name><surname>Petersson</surname><given-names>IF</given-names></name><name><surname>Karlsson</surname><given-names>KE</given-names></name><name><surname>Jonsson</surname><given-names>EN</given-names></name><name><surname>Mansson</surname><given-names>B</given-names></name><name><surname>Heinegard</surname><given-names>D</given-names></name><name><surname>Saxne</surname><given-names>T</given-names></name></person-group><article-title>Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><year>2006</year><volume>65</volume><fpage>1490</fpage><lpage>1494</lpage><pub-id pub-id-type="pmid">16707535</pub-id><pub-id pub-id-type="doi">10.1136/ard.2005.051292</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Study design</bold>. Blood-sampling procedures during the study from study baseline at -3 weeks to the end of the study at 24 weeks. Blood samples were obtained before and after 60 minutes exercise/rest at each occasion. The arrows indicates blood-sampling occasions. Two blood-samples at each occasions, with an hour apart.</p></caption><graphic xlink:href="1471-2474-7-98-1"></graphic></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Serum COMP at start of study</bold>. Serum concentration of COMP at week -3, before intervention, in study 1. Each line represents an individual patient. Horizontal bars show median values for each group.</p></caption><graphic xlink:href="1471-2474-7-98-2"></graphic></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Serum COMP during intervention</bold>. Serum concentrations of COMP at weeks 0 and 6 in the exercise group in study 1. Each line represents an individual patient. Horizontal bars show median values for each sampling occasion.</p></caption><graphic xlink:href="1471-2474-7-98-3"></graphic></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Serum COMP after standardised exercise in seven patients recruited from the exercise group in study 1</bold>. Serum COMP concentrations after a one-hour supervised exercise session in 7 patients, study 2. Each line represents an individual patient. The inserted figure shows serum COMP concentration in percent of baseline after a one-hour supervised exercise session.</p></caption><graphic xlink:href="1471-2474-7-98-4"></graphic></fig></sec></back></article>